Subject with Left ventricular ejection fraction (LVEF) below institutional normal range

Subject with metastasis to the central nervous system UNLESS asymptomatic and clinically stable

Subject with current active malignancy other than breast cancer

Subject with prior history of other malignancy except for cancers from which the patient is currently disease free

Subject with significant renal or hepatic dysfunction

Subject with history of venous or arterial thrombosis or risk factor for thrombosis other than history of malignancy

Subject with insufficient bone marrow function

Subject with contraindication to vinorelbine, trastuzumab, aspirin and/or warfarin therapy.

Subject with current active bacterial, Hepatitis B or C, and/or HIV infections

Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer